Benzinga | May 10, 2021 07:34AM EDT

Biohaven Pharmaceutical Q1 EPS $(2.97) Misses $(2.82) Estimate, Sales $43.82M Beat $40.63M Estimate

Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(2.97) per share which missed the analyst consensus estimate of $(2.82) by 5.32 percent. This is a 24.27 percent decrease over losses of $(2.39) per share from the same period last year. The company reported quarterly sales of $43.82 million which beat the analyst consensus estimate of $40.63 million by 7.86 percent. This is a 3.71K percent increase over sales of $1.15 million the same period last year.